Scarica l'app Stockscreener
261.77
1.81%
4.65
Dopo l'orario di chiusura:
261.39
-0.38
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$257.12
Aprire:
$261.67
Volume 24 ore:
4.45M
Relative Volume:
0.73
Capitalizzazione di mercato:
$462.58B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
129.12
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
+2.07%
1M Prestazione:
+4.93%
6M Prestazione:
+19.16%
1 anno Prestazione:
+19.89%
Intervallo 1D:
$260.10
$264.65
Intervallo di 1 settimana:
$246.77
$264.65
Portata 52W:
$190.75
$267.47
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
261.77 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,138.28 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.32 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
144.85 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
138.99 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-08-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2026-04-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Stock Rises as Management Details Pipeline Momentum at Wells Fargo Healthcare Conference - TIKR.com
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? - finance.yahoo.com
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon - Barchart.com
AbbVie Seeks To Nix Health Orgs' 'New Theory' In 340B Row - Law360
Can AbbVie (NYSE:ABBV) Defend Its Dividend Appeal? - Kalkine Media
Is AbbVie Stock Actually Overpriced? - Yahoo Finance
AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV - TipRanks
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - qz.com
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial - Endpoints News
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
What's Going On With AbbVie Stock Friday? - Benzinga
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study - Yahoo Finance
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win - Yahoo Finance
AbbVie extends migraine leadership with positive Phase III atogepant results - thepharmaletter.com
AbbVie stock heads into the open after a 1.6% gain - ad-hoc-news.de
AbbVie declares $1.73 quarterly dividend payable Nov 16 to shareholders of record Oct 15 - Pluang
AbbVie, Eli Lilly Place Multi-Billion-Dollar Bets on Immunology Drugs in Race for Next Blockbuster - finance.biggo.com
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Share Price Today (ABBV) | Live Chart, News & Stock Market - TechGraph
Abbvie Declares Quarterly Dividend, Payable on November 16, 2026 - marketscreener.com
AbbVie declares quarterly dividend of $1.73 per share - Investing.com
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com India
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Gains as Qulipta Opens a New Migraine Market - Yahoo! Finance Canada
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine - Investing News Network
AbbVie reports positive Phase 3 migraine trial results - grafa.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - Benzinga
AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story - ad-hoc-news.de
ABBV Maintained by HSBC -- Price Target Raised to $315 - GuruFocus
AbbVie's menstrual migraine treatment meets late-stage study goal - Reuters
Why Has AbbVie Gone Quiet About Humira? - Trefis
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX) - Seeking Alpha
AbbVie’s migraine treatment meets late-stage study goal - 1450 AM 99.7 FM WHTC
AbbVie reports positive phase 3 trial for menstrual migraine drug By Investing.com - Investing.com Canada
No treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial. - Stock Titan
UChicago Medicine names Kimyatta Washington Chief Operating Officer of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - TradingView
AbbVie at Wells Fargo healthcare conference: growth beyond immunology By Investing.com - Investing.com UK
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
AbbVie stock slips as Q2 revenue rises 10.2 percent - ad-hoc-news.de
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - ad-hoc-news.de
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - ad-hoc-news.de
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):